Glutathione-depleting photosensitizers for tumor-specific imaging and pyroptosis-driven photodynamic therapy

<b>Rationale:</b> Selective initiation of pyroptosis in malignant cells can amplify the immunological benefits of photodynamic therapy (PDT), but conventional photosensitizers (PSs) often lack tumor specificity and require complex subcellular targeting motifs. Here we describe a glutathione (GSH)-responsive PDT platform based on PSs that integrate fluorescence turn-on, GSH depletion, and restoration of reactive oxygen species (ROS) generation into a single molecular design. <b>Methods:</b> GSH-activated photosensitizers MTP-NO<sub>2</sub> and NTP-NO<sub>2</sub> were synthesized based on donor-acceptor structure, with their GSH-triggered activation, GSH depletion, ROS restoration, and caspase-1/GSDMD-mediated pyroptosis systematically demonstrated in 4T1 cells, while tumor accumulation, biodistribution, <i>in vivo</i> activation, and photodynamic antitumor efficacy of PSs nanoparticles were comprehensively assessed in 4T1 tumor-bearing mice through fluorescence imaging and immunohistochemical analyses. <b>Results:</b> Among a library of donor-acceptor scaffolds, the π-extended acene derivative NTP-NO<sub>2</sub>, equipped with a para-dinitrophenoxybenzyl pyridinium quencher, exhibited strong optical activation and ROS production upon reaction with elevated GSH in tumor cells. This dual action, antioxidant depletion and ROS restoration, triggered caspase-1/gasdermin-D-mediated pyroptosis, IL-1β/IL-18 release, and robust immunogenic cell death. Nanoparticle delivery of NTP-NO<sub>2</sub> achieved high tumor accumulation, precise imaging, and pronounced antitumor efficacy <i>in vivo</i>. <b>Conclusion:</b> By exploiting tumor GSH overexpression-activated photodynamic therapy, the NTP-NO<sub>2</sub> depletes GSH and promotes caspase-1/GSDMD pathway to trigger robust pyroptosis, eliciting inflammatory/immune responses both <i>in vitro</i> and <i>in vivo</i>. This chemically defined approach provides a PS design that unites selective activation, immune-stimulatory cell death, and precise photodynamic tumor ablation.

Authors

Institutions

Publication Details

Journal
Theranostics
Published
2025-11-20
DOI
https://doi.org/10.7150/thno.124154
Citations
1
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.67

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glutathione-depleting photosensitizers for tumor-specific imaging and pyroptosis-driven photodynamic therapy

Fang Hu, Pei Chen, Yajun Lin, Jucai Gao et al.
1 citations
Theranostics
Nanoplatforms for cancer theranostics
0.67
article

Glutathione-depleting photosensitizers for tumor-specific imaging and pyroptosis-driven photodynamic therapy

Fang Hu, Pei Chen, Yajun Lin, Jucai Gao, Zhengyumeng Zhu, Qiang Wang, Yifei Yang, Hui Yang
article en
1 citations

Abstract

<b>Rationale:</b> Selective initiation of pyroptosis in malignant cells can amplify the immunological benefits of photodynamic therapy (PDT), but conventional photosensitizers (PSs) often lack tumor specificity and require complex subcellular targeting motifs. Here we describe a glutathione (GSH)-responsive PDT platform based on PSs that integrate fluorescence turn-on, GSH depletion, and restoration of reactive oxygen species (ROS) generation into a single molecular design. <b>Methods:</b> GSH-activated photosensitizers MTP-NO<sub>2</sub> and NTP-NO<sub>2</sub> were synthesized based on donor-acceptor structure, with their GSH-triggered activation, GSH depletion, ROS restoration, and caspase-1/GSDMD-mediated pyroptosis systematically demonstrated in 4T1 cells, while tumor accumulation, biodistribution, <i>in vivo</i> activation, and photodynamic antitumor efficacy of PSs nanoparticles were comprehensively assessed in 4T1 tumor-bearing mice through fluorescence imaging and immunohistochemical analyses. <b>Results:</b> Among a library of donor-acceptor scaffolds, the π-extended acene derivative NTP-NO<sub>2</sub>, equipped with a para-dinitrophenoxybenzyl pyridinium quencher, exhibited strong optical activation and ROS production upon reaction with elevated GSH in tumor cells. This dual action, antioxidant depletion and ROS restoration, triggered caspase-1/gasdermin-D-mediated pyroptosis, IL-1β/IL-18 release, and robust immunogenic cell death. Nanoparticle delivery of NTP-NO<sub>2</sub> achieved high tumor accumulation, precise imaging, and pronounced antitumor efficacy <i>in vivo</i>. <b>Conclusion:</b> By exploiting tumor GSH overexpression-activated photodynamic therapy, the NTP-NO<sub>2</sub> depletes GSH and promotes caspase-1/GSDMD pathway to trigger robust pyroptosis, eliciting inflammatory/immune responses both <i>in vitro</i> and <i>in vivo</i>. This chemically defined approach provides a PS design that unites selective activation, immune-stimulatory cell death, and precise photodynamic tumor ablation.

TheranosticsVol. 16(4)
Gannan Medical University (CN), Beijing National Laboratory for Molecular Sciences (CN), Southern Medical University (CN)
National Natural Science Foundation of China, Jiangxi Provincial Department of Science and Technology, Gannan Medical University, National Key Research and Development Program of China, Beijing National Laboratory for Molecular Sciences
Openalex Percentile: Top 25%
Nanoplatforms for cancer theranostics
0.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.